Malaria vaccine implementation programme
As of October 2023, WHO recommends the programmatic use of malaria vaccines for the prevention of P. falciparum malaria in children living in malaria endemic areas, prioritizing areas of moderate and high transmission. This applies to both RTS,S/AS01 and R21/Matrix-M vaccines.
The first malaria vaccine, RTS,S, was recommended by WHO to prevent malaria in children in October 2021. The vaccine has reached nearly 2 million children in Ghana, Kenya and Malawi through the Malaria Vaccine Implementation Programme, MVIP, since 2019.
News
All →Multimedia
Q&As
Multimedia
Video: Lifesaving malaria vaccine: harnessing innovation to fight an ancient killer
Countries
SAGE/MPAG Working Group
Technical background
This Framework is intended to be dynamic to support prioritization decisions at the start of vaccine roll-out and over the coming years as supply ramps...
External publications
(The New England Journal of Medicine, DOI: 10.1056/NEJMoa2026330, p13, 25 August 2021)
Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention
Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention
(The Lancet, Vol 386, No.9988, p31-45, 4 July 2015)
Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial
Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial
(The Lancet, Vol 387, No. 10016, p367–375, 23 January 2016)
Penny MA, et al. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models
Penny MA, et al. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models
